Alumis Inc. (NASDAQ:ALMS) Receives $27.50 Average PT from Analysts

Shares of Alumis Inc. (NASDAQ:ALMS) have received a consensus rating of “Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $26.83.

Several research analysts have recently weighed in on ALMS shares. Leerink Partners initiated coverage on shares of Alumis in a report on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 price target on the stock. Baird R W upgraded Alumis to a “strong-buy” rating in a report on Thursday, October 31st. HC Wainwright decreased their price target on shares of Alumis from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday. Robert W. Baird initiated coverage on shares of Alumis in a research note on Thursday, October 31st. They set an “outperform” rating and a $25.00 target price on the stock. Finally, Morgan Stanley began coverage on shares of Alumis in a research note on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 price target on the stock.

Alumis Trading Down 6.0 %

ALMS stock opened at $8.85 on Monday. Alumis has a 12-month low of $8.23 and a 12-month high of $13.53. The firm has a fifty day moving average price of $11.29.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($23.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($21.53). Equities analysts anticipate that Alumis will post -8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ALMS. BNP Paribas Financial Markets acquired a new stake in Alumis during the third quarter worth $27,000. MetLife Investment Management LLC purchased a new position in shares of Alumis in the 3rd quarter valued at $89,000. Barclays PLC acquired a new stake in Alumis during the 3rd quarter worth $197,000. Maven Securities LTD acquired a new stake in shares of Alumis during the second quarter worth $332,000. Finally, State Street Corp purchased a new position in shares of Alumis during the 3rd quarter worth approximately $866,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.